EMA's Advisory Committee Recommends Approval Of Bristol-Myers' Breyanzi In Lymphoma


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bristol-Myers Squibb Co BMY Breyanzi (lisocabtagene maraleucel; liso-cel) for lymphoma settings.

  • The recommendation covers Breyanzi for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more lines of systemic therapy.
  • The CHMP adopted a positive opinion based on TRANSCEND NHL 001, and additional data from the TRANSCEND WORLD study. 
  • The EC is expected to deliver its final decision within 67 days of receiving the CHMP opinion.
  • Price Action: BMY shares are up 0.77% at $64.35 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!